TENX

Business Context and Reporting Period

Company: Synthetic Blood International, Inc. (Note: Metadata listed "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Reporting Period: Quarterly period ended January 31, 2003 (Nine months ended January 31, 2003 for comparative data).
Status: Development Stage Company. The firm is in the pre-clinical trial stage for its perfluorocarbon-based blood substitute, Oxycyte. An Investigational New Drug (IND) application was submitted to the FDA on February 6, 2003, to initiate Phase I safety studies.

Key Financial Metrics

Note: The filing text contains significant formatting anomalies in the "Statements of Operations" table where large cumulative deficit figures appear in the column headers for the three-month period. The values used above for the three-month period are derived from the "Results of Operations" narrative text which explicitly states the net loss was $464,498.

Material Changes vs. Prior Period

• Research & Development (R&D):
  • Three Months: Decreased to $243,214 from $328,719 in the prior year, primarily due to the closure of the Ohio research laboratory ($81,000 reduction in salaries/consulting).
  • Nine Months: Increased to $1,256,761 from $996,044 in the prior year, driven by a significant increase in animal research studies ($230,000 increase in contract/consulting/salary expenses).
• General & Administrative (G&A):
  • Three Months: Increased to $230,419 from $172,398 due to higher legal fees ($31,000), insurance ($9,000), and Ohio lab closure costs ($14,000).
  • Nine Months: Increased to $673,433 from $623,499 for similar reasons.
• Liquidity: Cash and cash equivalents declined from $2,442,015 (April 30, 2002) to $524,429 (January 31, 2003). The company utilized $1,755,365 in cash for operating activities over the nine-month period.
• Other Income: Decreased significantly due to lower interest rates and reduced invested balances, contributing to a wider net loss despite expense reductions in the three-month period.

Outlook, Risks, and Management Commentary

• Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern. Continuation depends on obtaining additional financing for development and testing.
• Liquidity Outlook: Management believes current cash ($524,429) is sufficient to meet projected needs through July 2003. However, this projection excludes the cost of conducting the Oxycyte Phase I clinical study.
• Financing Needs: The company has no firm commitments for additional capital. It is actively pursuing private/institutional financing and strategic alliances. Failure to raise funds may force delays, scaling back of programs, or selling technology rights.
• Regulatory Risks: Success depends on FDA approval of the IND application and subsequent clinical trials. There is no assurance that products will be found safe/effective or that market acceptance will be achieved.
• Unusual Items: The company issued 170,000 shares of common stock for legal services ($30,600 expense) and granted 400,000 stock options to employees during the period.

Investor Verification Checklist

• Capital Sufficiency: Verify if the company has secured the funding required to launch the Oxycyte Phase I study, as current cash reserves do not cover this cost.
• IND Status: Confirm the FDA's response to the Investigational New Drug application submitted on February 6, 2003.
• Expense Run Rate: Assess the sustainability of the current burn rate (~$1.9M loss over nine months) against the remaining cash balance of ~$524k.
• Dilution Risk: Monitor for potential equity issuances required to fund operations, which would dilute existing shareholders.
• Operational Footprint: Confirm the status of the Ohio laboratory closure and the impact on future R&D capabilities.